Summary InDex Pharmaceuticals Holding AB (InDex Pharmaceuticals) is a pharmaceutical company that offers treatments for immunological diseases.The company’s lead compound cobitolimod, currently in the phase 2 stage, is intended for the treatment of moderate to severe treatment active refractory ulcerative colitis.
Its preclinical products include DIMS 9054, and DIMS 9059, which are intended for treating resistant pulmonary inflammation and cancer.InDex Pharmaceuticals offers dibicol, a PCR-based method that monitors proprietary biomarkers used for ulcerative colitis.
The company conducts clinical studies in the Czech Republic, France, Germany, Hungary, Spain, Russia, Italy, Poland, Romania, Serbia, Sweden, and Ukraine. InDex Pharmaceuticals is headquartered in Stockholm, Sweden.
InDex Pharmaceuticals Holding AB (INDEX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings.The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period.
The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope - Financial Deals - Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. - Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector. - Major Deals - Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios. - Business Description - A brief description of the company’s operations. - Key Employees - A list of the key executives of the company. - Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company. - Key Competitors - A list of the key competitors of the company. - Key Recent Developments - A brief on recent news about the company.
Reasons to Buy Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements - The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy - The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Our reports have been used by over 10K customers, including:
Vitiligo - Pipeline Review, H2 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Vitiligo - Pipeline Review, H2 2020, provides an overview of the Vitiligo (Dermatology) pipeline landscape. Vitiligo is a condition in which skin loses melanin, the pigment that determines...
Vasculitis Disease - Global Clinical Trials Review, H2 2020 Summary clinical trial report, “Vasculitis Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Vasculitis Clinical trials scenario.This report provides top line data relating to the clinical trials on Vasculitis. Report...
Glomerulonephritis - Pipeline Review, H2 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Glomerulonephritis - Pipeline Review, H2 2020, provides an overview of the Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline landscape. Glomerulonephritis...
Global Infectious Diseases Partnering 2014 to 2020 provides the full collection of Infectious Diseases disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014. Trends in Infectious Diseases partnering deals Financial deal terms for headline, upfront and royalty by stage of development Infectious...